MARCH 17, 2015
OsteoRemedies® appoints Eric A. Stookey as Chief Operating Officer
OsteoRemedies, LLC, a company focused on providing simple solutions to complex disorders currently not addressed in the musculoskeletal market, is pleased to announce Eric A. Stookey has been appointed Chief Operating Officer, effective March 1, 2015.
“In 2015, we plan to introduce new products, enter new markets, and expand our hip and knee surgeon network,” stated Chris Hughes, President and Chief Executive Officer of OsteoRemedies. “Eric’s tremendous experience and pattern of success in orthopedics is exactly what we need to successfully execute our strategic plan and allow OsteoRemedies to uniquely serve our surgeon customers’ clinical needs.”
Prior to joining OsteoRemedies, Mr. Stookey most recently served as the President of the Extremities-Biologics division at Wright Medical Group, Inc. (Nasdaq:WMGI) until August 2014. Mr. Stookey served in various other marketing and sales positions at Wright Medical Group, Inc. since 1995, including the Senior Vice President and Chief Commercial Officer, Vice President North American Sales, Senior Director of Sales – Central Region, and Director of Marketing for Large Joint Reconstruction Products. He also worked for DePuy Orthopedics, Inc. from 1993 to 1995.
Mr. Stookey earned his Masters of Business Administration degree from Christian Brothers University and his Bachelor of Science degree in Business from the Indiana University School of Business. In addition to his new role as Chief Operating Officer, Mr. Stookey will continue to serve as an independent member of the Board of Directors for both Amedica Corporation, Salt Lake City, UT (Nasdaq: AMDI) and Cartiva, Inc., Alpharetta, GA.
“I am delighted to be joining the OsteoRemedies team to help build upon the excellent foundation and momentum Chris has established over the past 12 months,” stated Mr. Stookey. “We absolutely share a vision for addressing unmet needs that allow clinicians to better treat their patients, and I’m excited to work with the world-class distributors to further expand this organization.”
OsteoRemedies will be exhibiting at the upcoming American Academy of Orthopedic Surgeons (AAOS), in Las Vegas, NV, on March 25-27 (Booth #4665). As part of this event, they will be displaying current differentiated products like the REMEDY® Spacer, UNITE® Antibiotic Bone Cement and unveiling new revision offerings that will further address unmet needs in the US orthopedic market.
About OsteoRemedies, LLC
OsteoRemedies provides simple procedural solutions to complex musculoskeletal disorders. Their first introduction in the orthopaedic market was the REMEDY Spacer System. This is the first FDA-approved modular system available for both hip and knee two-stage infection revision arthroplasty. The REMEDY Spacer is indicated for temporary use (maximum 180 days) as an adjunct to total hip or knee replacement in skeletally mature patients undergoing a two-stage procedure due to a septic process and where gentamicin is the most appropriate antibiotic based on the susceptibility pattern of the infecting micro-organisms. Their second product was the UNITE AB Bone Cement product line. UNITE is available in a 40 gram batch loaded with gentamicin.
President and CEO